Maagensen, Henrik
Helsted, Mads M.
Gasbjerg, Lærke S.
Vilsbøll, Tina
Knop, Filip K. http://orcid.org/0000-0002-2495-5034
Article History
Accepted: 3 November 2022
First Online: 28 November 2022
Declarations
:
: H.M. and M.M.H declare no conflict of interest. L.S.G. is minority shareholder of Antag Therapeutics. T.V. has served on scientific advisory panels, been part of speaker’s bureaus for, served as a consultant to and/or received research support from Abbot, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, MSD/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals. F.K.K. has served on scientific advisory panels, been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Norgine, Novo Nordisk, Sanofi, ShouTi, SNIPR Biome, Zealand Pharma and Zucara; and is a minority shareholder of Antag Therapeutics.
: This article does not contain original data from studies with human or animal subjects.